Talphera, Inc.TLPH
What Talphera, Inc. does.
We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.
Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT. In addition, we may develop LTX-608, a nafamostat formulation for direct IV infusion for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment. We have two pre-filled syringe product candidates that have been explored but are being evaluated for discontinuation.
In January 2022, we acquired Lowell Therapeutics, Inc., or Lowell, a privately held company, pursuant to the Agreement and Plan of Merger, dated as of November 14, 2021, or the Merger Agreement, in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments, and which included up to approximately $26.0 million of contingent consideration payable in cash or stock at our option, upon the achievement of regulatory and sales-based milestones. In connection with the Merger Agreement, we acquired Niyad and LTX-608 (lyophilized vials of nafamostat for infusion into the extracorporeal circuit or direct IV infusion to the patient, respectively), an in-process research and development, or IPR&D, asset. For additional information regarding the Merger Agreement, see Note 4, “Asset Acquisition” to our consolidated financial statements in this Annual Report on Form 10-K.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.4M | $2.8M | $0 | $651,000 | $0 | $28,000 |
| Net income | -$40.4M | -$35.1M | $47.8M | -$18.4M | -$13.0M | -$14.3M |
| Free cash flow | -$40.4M | -$31.8M | -$28.7M | -$17.6M | -$12.7M | — |
More on TLPH.
- Talphera, Inc. summary
- Talphera, Inc. financial statements
- Talphera, Inc. key metrics
- Talphera, Inc. health scores and style box
- Talphera, Inc. earnings
- Talphera, Inc. dividends
- Talphera, Inc. valuation
- Talphera, Inc. ownership and insiders
- Talphera, Inc. peers
Figures from Talphera, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.